Psycon Las Vegas 2024

PSYCON LAS VEGAS: NAVIGATING TAX CHALLENGES IN THE PSYCHEDELIC INDUSTRY

Taxation Challenges in the Psychedelic Industries

At the recent PsyCon Convention in Las Vegas, Justin Botillier of Calyx CPA based in Medford, Oregon, delivered a critical presentation addressing the intersection of taxation challenges within the cannabis and psychedelics industries. With deep expertise in cannabis taxation, Justin offered insights that are particularly relevant to both sectors, especially regarding IRS Section 280E.

 

Understanding IRS Section 280E and Its Broad Implications

The core of Justin’s presentation centered on IRS Section 280E. Initially implemented during the war on drugs in the early 1980s, Section 280E prohibits businesses involved with Schedule I or II controlled substances from deducting typical business expenses, except for the Cost of Goods Sold (COGS). Justin detailed how this section affects the psychedelics and cannabis businesses, creating significant financial hurdles due to the inability to deduct ordinary business expenses.

 

Insights for the Psychedelics Industry

While he put much focus on cannabis, Justin effectively bridged the conversation to include the psychedelics industry, which faces similar challenges and uncertainties regarding taxation and regulation. As the psychedelics sector continues to evolve, understanding the application of tax laws like 280E becomes crucial for business owners and investors within this space.

 

Strategic Tax Planning for Cannabis and Psychedelics

Bifurcation Strategy

Justin outlined a bifurcation strategy recommended by other professionals working in the psychedelics space to mitigate the tax burden of 280E. By splitting operations into two entities — one for plant-touching activities and another for non-plant-touching activities — businesses can optimize their tax filings.

Single Entity Strategy

For businesses that prefer a unified operational model, Justin discussed the benefits of a single-entity strategy, emphasizing rigorous accounting practices to allocate costs properly and maximize allowable deductions excluded by 280E. This approach requires a solid understanding of IRC Section 471c, which he explained in detail, demonstrating how careful inventory costing can shield a business from excessive tax liabilities.

 

IRC Section 471c: A Tool for Compliance and Optimization

Explaining the nuances of IRC Section 471c, Justin highlighted how this section allows for greater flexibility in accounting for inventory costs, thereby increasing deductible COGS. This is vital for both cannabis and psychedelic businesses seeking to navigate the limitations imposed by 280E effectively.

 

Anticipating Future Legal and Regulatory Shifts

Justin speculated on potential shifts in drug policy and legal frameworks that could impact the application of 280E to both cannabis and psychedelic businesses. He discussed possible rescheduling efforts and new regulatory developments, suggesting that changes in the legal landscape could mitigate some of the current challenges faced under 280E, beyond just rescheduling cannabis.

 

Expert Guidance for Navigating Complex Tax Landscapes

Concluding his presentation at PsyCon, Justin Botillier emphasized the importance of engaging with tax professionals who specialize in cannabis and, increasingly, in psychedelics. As the regulatory environments evolve, his insights into effective tax planning provide a roadmap for businesses to navigate these complex fields while maintaining compliance and optimizing financial outcomes.


Justin warns that beyond concerns about the ramifications of IRS audits, companies operating in “trafficking” businesses need to be extremely careful about whom they choose to file tax returns. More often than not, it is the accountant who will mire their clients in tax debt rather than the IRS.

ContactUs

Simply fill out the form and we will be in touch to answer any of your queries, 

And feel free to check out our blog & video Section for more info.

Psychedelics Oregon

CALIFORNIA’S PIONEERING LEGISLATION FOR PSYCHEDELIC THERAPY

California’s Pioneering Legislation for Psychedelic Therapy

In an era where mental health innovation is more crucial than ever, California stands at the forefront of a transformative shift. The recent passage of Senate Bill 1012, introduced by Sen. Scott Wiener, marks a significant development in the use of psychedelics for therapeutic purposes. Here’s a deep dive into what this groundbreaking legislation entails and its potential ripple effects, particularly for states like Oregon.

A New Dawn for Psychedelic Therapy

Under SB 1012, California is set to establish regulated service centers where adults aged 21 and older can access substances such as psilocybin, MDMA, mescaline, and DMT in a professionally supervised setting. This initiative, aptly named the “Regulated Therapeutic Access to Psychedelics Act,” is not merely about accessibility but is structured to ensure safety and efficacy through stringent oversight (Marijuana Moment).

The Framework of Regulation

The proposed service centers will operate under the aegis of the newly formed Division of Regulated Psychedelic Substances Control within the California Department of Consumer Affairs. This division will oversee the training and licensing of facilitators who must hold medical licenses, thereby ensuring that participants are in capable hands. This regulatory mechanism aims to foster a safe environment for those exploring psychedelic therapies as avenues for profound healing (KQED).

Health Safeguards and Accessibility

Participants in the program will undergo thorough health and safety screenings to tailor their experiences safely. The bill interestingly does not limit access to individuals with predefined medical conditions, broadening the potential benefits to a wider audience. It also emphasizes the importance of follow-up care, which includes integration services to help individuals process their experiences meaningfully (The Marijuana Herald).

The Broader Implications

Proponents of the bill argue that psychedelics hold immense potential in treating conditions resistant to conventional treatments, such as severe depression and PTSD. This legislation comes in response to Governor Gavin Newsom’s earlier veto of a more extensive decriminalization bill, signaling a cautious but progressive approach towards psychedelic therapy. The governor’s guidance has shaped this legislation to focus more narrowly on therapeutic use, ensuring that it’s paired with appropriate safety protocols (Marijuana Moment).

What This Means for Oregon and Beyond

California’s legislative advancements serve as a potential blueprint for other states, including Oregon, which has shown interest in similar reforms. The Oregon community, particularly businesses and healthcare providers, should closely monitor California’s rollout and outcomes to adapt and prepare for possible legislative shifts in their state. This movement isn’t just about changing laws but is a part of a larger shift towards integrating more holistic and progressive treatments into mental health care (DoubleBlind Mag).

As this bill progresses through further legislative stages, it will be crucial to watch how it influences not only the landscape of mental health treatment in California but also sets a precedent for other states considering similar pathways. For professionals and businesses in the cannabis and psychedelic sectors in Oregon, staying informed and prepared is key to navigating the potential changes that might come with such legislative models.

In essence, California’s move towards regulated psychedelic therapy is a beacon of innovation in mental health care, providing a glimpse into a future where these powerful substances are harnessed safely and effectively to heal and transform lives.

INTERVIEWING BRITT ROLLINS, CEO OF THE NATIONAL PSYCHEDELICS ASSOCIATION

Navigating the Psychedelics Industry: How the National Psychedelics Association is Pioneering Change

The Psychedelics Industry, once a fringe sector, has rapidly evolved into a significant area of interest for both investors and healthcare professionals alike. At the forefront of this burgeoning industry is the National Psychedelics Association (NPA), a pioneering body dedicated to facilitating the growth and regulatory navigation of psychedelic-related businesses. The NPA plays a crucial role in addressing both the opportunities and challenges encountered by those within this space, particularly in relation to financial services, business solutions, and legislative advocacy. This article delves into the comprehensive efforts of the NPA to support the psychedelics community and foster an environment conducive to the sector’s sustainable development.

Introduction to the National Psychedelics Association

The National Psychedelics Association (NPA), established with the vision of supporting the evolving needs of the psychedelics industry, serves as a beacon for those navigating the complex landscape of psychedelic substances. With a focus on promoting safe, ethical, and legal access, the NPA provides invaluable resources, including regulatory guidance, business support, and educational services. As the industry burgeons, the association’s role in uniting businesses, researchers, and enthusiasts becomes increasingly vital, ensuring the psychedelic movement progresses with integrity and professionalism.

Challenges with Banking and Financial Services

One of the most pressing obstacles faced by businesses within the psychedelics industry is the limited access to banking and financial services. Given the legal ambiguities and evolving regulations surrounding psychedelics, many financial institutions are hesitant to engage with businesses in this sector. This hesitancy can stifle growth, limiting companies’ abilities to secure funding, process payments, and manage operations efficiently. Recognizing these challenges, the NPA actively works with stakeholders to bridge the gap, advocating for clearer regulations and fostering relationships with financial institutions open to supporting the industry.

Efforts to Provide Business Solutions

In response to the unique demands of the psychedelics market, the National Psychedelics Association has embarked on a mission to deliver targeted business solutions. These efforts include offering strategic advice, facilitating networking opportunities, and providing insights into best practices for navigating the market. Furthermore, the NPA is instrumental in advocating for changes that could alleviate some of the financial and operational burdens on businesses, aiming to cultivate a thriving and competitive industry landscape.

Support for Service Centers

Service centers, such as therapeutic clinics and research facilities, constitute a critical component of the psychedelics ecosystem. The NPA recognizes the challenges such establishments face, from regulatory hurdles to logistical complexities. To address these issues, the association offers tailored support encompassing regulatory compliance, staff education, and community-building initiatives. This comprehensive approach ensures that service centers can deliver their invaluable services effectively and within legal bounds.

Guidance for Industry Professionals

The evolving landscape of the psychedelics industry necessitates continuous learning and adaptation by its professionals. The National Psychedelics Association acknowledges this need by providing a plethora of educational resources, workshops, and seminars geared towards enhancing the knowledge and skills of industry participants. By equipping professionals with the latest information on legislation, research, and market trends, the NPA empowers individuals to navigate the industry with confidence and contribute positively to its development. In conclusion, the National Psychedelics Association stands at the vanguard of the psychedelics movement, tirelessly working to address the sector’s multifaceted challenges while promoting growth and innovation. Through its comprehensive support services and advocacy efforts, the NPA is pioneering change, laying the groundwork for a future where the psychedelics industry flourishes, benefiting individuals and society at large.

NAVIGATING THE COMPLEXITIES OF 280E, 471(C), CHAMP, & STRATEGIES FOR PSILOCYBIN SERVICE CENTERS.

Insights into Oregon’s Psilocybin Service Centers

Enlightening Insights into Oregon’s Psilocybin Service Centers

In this enlightening conversation, Justin Botillier, CEO of Calyx CPA in Medford, Oregon, alongside Michael Brooks, who is venturing into Oregon’s burgeoning psilocybin industry, delve deep into some of the most pressing questions faced by psilocybin service centers today.

Addressing IRS Code Section 280E and Its Implications

Addressing the intricacies of Section 280E of the IRS code, they explore its profound implications on the psilocybin industry, particularly service centers, drawing parallels and distinctions with the cannabis industry’s ongoing struggle.

Comprehensive Strategies to Mitigate 280E’s Impact

With a comprehensive analysis, Justin provides a thorough breakdown of the strategies to mitigate 280E’s impact, including the use of 471(c) and the CHAMP (Californians Helping to Alleviate Medical Problems) case as pivotal references for tax planning and business structuring.

Selecting the Appropriate Business Entity

Furthermore, the discussion covers the essential considerations for choosing the appropriate business entity, emphasizing the unique challenges and opportunities within the psilocybin sector.

Navigating Banking and Financial Operations

They also touch upon banking difficulties, offering practical advice for navigating financial operations amidst federal restrictions.

Understanding the Federal Climate and Potential Changes

Justin sheds light on the current federal climate surrounding 280E and the potential for significant legal and regulatory changes, highlighting the importance of strategic planning and robust record-keeping.

This video is a must-watch for anyone involved in or considering entering the psilocybin industry, offering valuable insights into tax strategies, business planning, and the evolving federal landscape. Whether you’re an established service center, a newcomer, or simply interested in the intersection of psychedelics and business, this discussion provides critical knowledge and guidance to navigate the complexities of operating within this unique and transformative space.

Mindfulness-Experience-Podcast-1-c29e19aa

THE MINDFULNESS EXPERIENCE PODCAST – IRS, 280E & PSYCHEDELICS Ideas

In this episode of The Mindfulness Experience Podcast, host Keith Fiveson interviews Botillier, CEO of Calyx CPA LLC, who has extensive experience working with small business owners and is a passionate advocate for the Cannabis and Psychedelic Industries. As a member of the psychedelic community, Justin is committed to assisting businesses in Oregon’s burgeoning psilocybin industry in navigating the financial implications of the 280E provision.

 
psilocybin-capsule-in-plate-of-loose-psilocybin-a0ac9764

280E AND THE PSILOCYBIN INDUSTRY

Like cannabis, psilocybin is a schedule one drug subject to tax code 280E. This writing will not go into what 280E is because, as the cannabis industry has been subject to the code section since its implementation in the early 80s, there is an abundance of information about 280E that can be found online. The question is how it impacts the psilocybin industry and what the industry can do about it. We have identified service centers as being the entity in the supply chain that would be most impacted by 280E. Manufacturers are similar to cannabis cultivators in that they are less affected by 280E; most, if not all, activity is related to the product’s manufacturing and, therefore, the company can comfortably deduct their expenses under inventory-related code section 471.

On the other hand, according to 280E, psilocybin Service Centers are not allowed to deduct almost all of their expenses except for the cost of the psilocybin itself. If you do the math, you will see how this tax treatment will be impossible for the industry to absorb. Therefore, a methodology must be utilized to mitigate the impact of 280E for Service Centers.

As of this writing, two methods are being entertained. One is the CHAMP method, and the other is a 471C methodology. This writing will explore the most logical approach, the CHAMP method.

To learn more about (CHAMP), google “Californians Helping to Alleviate Medical Problems (CHAMP) v Commissioner.” Warning, as an approach has yet to be tried in court, there is no risk-free method to mitigating the impact of 280E. Psilocybin Service Centers are expected to start operations in September of 2023, tax returns will be filed in 2024, and audits will likely not be conducted for a few years after that. Therefore, we will not know what methodology will be allowed until a tax return is tried in tax court and litigated.

CALIFORNIANS HELPING TO ALLEVIATE MEDICAL PROBLEMS (CHAMP)

Californians Helping to Alleviate Medical Problems (CHAMP) was a 501c3 not-for-profit organization that provided medical services supplemented with cannabis. Unfortunately, they were audited by the IRS, their nonprofit status was stripped, and they were assessed tax at corporate rates of 35%. As a result of 280E, all of their expenses, except for the cost of their product purchased for resale (COGS), were disallowed. The tax treatment ultimately forced the organization to close. Fortunately for those in the psilocybin industry, CHAMP appealed the decision and eventually won their argument. Their attorneys successfully argued that the organization’s primary operation was to provide medical care, and selling cannabis was a secondary activity. As a result, the court decided to allow the organization to deduct its expenses related to caregiving. There are many more facts and circumstances related to the case, but for the psilocybin industry, it’s a start.

Along with most would-be business owners in the psilocybin industry, our firm also believes that, like the cannabis industry, psilocybin can be used for medicinal purposes. However, despite mounting support for the hypothesis, evidence is still inconclusive due to legal barriers. However, using psychedelics for therapeutic purposes does indicate a higher efficacy rate than talk therapy to treat mental illnesses, including OCD, PTSD, and addiction.

Please note that the strategy of having multiple business activities has been attempted by the cannabis industry numerous times but has failed many more times because their “services” or “other” business activities were deemed to be an attempt to circumvent 280E or were in the service of selling cannabis and were not legitimate revenue streams. However, I think the psilocybin industry can leverage the CHAMP precedence in that most Service Centers or business people in the sector intend to operate a business meant to help people, and selling psilocybin is in the service of caregiving.

Therefore, with proper accounting and recordkeeping, we, as accounts, should be able to argue that the industry is generating revenue by offering services and not necessarily selling psilocybin. But, of course, we will not allow all expenses; we must throw the IRS a bone and disallow the overhead related to “drug trafficking.” At that point, we can, however, implement the 471C approach to allocate costs associated with the sale of psilocybin.

Unfortunately, there is no silver bullet. Accordingly, the IRS has concluded that, along with ancillary, closely held companies, or businesses that do not have substantially different ownership, any trafficking within a company or a group of companies can taint their business activities and make them subject to 280E.

471C

It has also been proposed that the industry take a purely 471C approach and, under it, deduct all its expenses, besides those that would not otherwise qualify as a requirement to do business, as discretionary expenses. But that approach would hold up more, or even less, than a dispensary attempting to do the same thing. One thing is for sure, your biggest concern is your accountant not doing anything and getting mired in tax debt.

admin-ajax (1)

280E AND PROPER BUSINESS STRUCTURES

Businesses subject to Internal Revenue Code Section 280E must choose their business structure carefully. In this article, I will describe the pros and cons of each structure, and provide recommendations for specific business types within the cannabis and psilocybin industry.

LIMITED LIABILITY COMPANY (LLC)

The Limited Liability Company (LLC) is now the most recommended legal structure. Many people automatically confuse LLCs with being synonymous with partnerships and, at one point, this was true. However, about 20 years ago, awareness started to change and now LLCs are considered for multiple tax treatments. For example, the LLC can be taxed as a sole proprietorship or disregarded entity, partnership, S corporation, or C corporation.

PARTNERSHIPS

Partnerships should only be considered when holding assets for investment purposes or when the ownership structure necessitates it. Partnerships are the most flexible tax structure allowing diverse ownership types, capitalization, and distribution activities. However, it is a pass-through entity in which the business’s income is taxed at the partner level, the income can be subject to self-employment tax and, due to the relatively new Partnership Audit Regime enforced by the IRS, when partnerships are audited they can be charged tax at the partnership level at the highest individual income tax rates. For this reason, we don’t recommend partnerships unless it is necessary.

S CORPORATION

Most small businesses qualify to elect to be taxed as an S corporation if they choose. Like the partnership entity structure, the S corporation is a pass-through entity, meaning the business’s net income is taxed at the shareholder level. However, if appropriately managed, the S corporation can be more tax favorable than a partnership or C corporation. For example, the S corporation business entity must pay its officers a “reasonable wage,” subject to payroll taxes. But unlike partnership distributions, distributions paid from an S corporation are not subject to the 15.3% self-employment tax.

For this reason, the S corporation is the preferred entity structure for small businesses. For most companies in the cannabis and psilocybin supply chain, the S corporation is typically ideal. However, a pass-through entity is not recommended for companies with a significant 280E impact, specifically retailers or service centers.

C CORPORATIONS

C corporations should be considered before other entities operating in a federally illegal business, specifically those in which 280E applies. Tax is assessed at the business level, and business returns are prepared independently of the shareholders’ tax returns. In addition, due to its current Federal tax rate of 21%, it can be more tax favorable for business owners subject to higher individual tax rates. But most importantly, if a tax adjustment results in significant tax debt, the corporation is siloed from the shareholders. The corporation is responsible for the tax debts imposed by the taxing authorities, not the owners.

There is frequent pushback when suggesting the use of C corporations. There is a concern over double taxation in that C corporations pay tax on their earnings and then again when those earnings are paid out in the form of dividends. There is potential for double taxation, but those results are typically due to the mismanagement of the corporation funds or the lack of tax planning. The C corporation is only subject to the potential of double taxation when the ownership is attempting to extract value from it. Otherwise, the income of a C corporation will be taxed only once.

Most business owners intend to expand their operations and business holdings. The corporation’s earnings can be used to expand operations, purchase additional assets, or lend to other companies. Therefore, they are not likely to be subject to double taxation during the growth phase of their development. The risk of double taxation happens when the shareholders attempt to extract value from the company. Fortunately, with some planning, there are various ways that earnings can be paid out to avoid being taxed a second time. For example, value can be extracted as compensation through the payroll system or paid out as management or consulting fees; it is common for corporations to give bonuses to key employees that are also shareholders. Often the shareholders of a corporation will set up consulting or management companies that provide services to the corporation in return for fees; shareholders can be paid for simply being on the board. Finally, paying rent is a common way of extracting value without being double-taxed. The corporation leases real estate, human resources, or equipment from companies the shareholders may also own.

An ideal structure, we recommend, is to have your trafficking operations included as a C corporation and your real estate holding company structured as a partnership. Furthermore, I recommend that your real estate company do as little commingling of activities with your operating company as possible. For example, it is common practice for the real estate holding company to provide land and leasehold improvements to customize the property to address the operating company’s needs. This activity could cause the holding company to be considered “in the service of” trafficking. Therefore, to help reinforce the holding company’s position that it is simply a real estate investment company and not in the business of trafficking, we recommend that “build-outs” and other related activities be paid from the operating company and included in the operating company’s bookkeeping.

Selecting the proper business structure is vital for the success and growth of any company, especially for those operating in federally illegal businesses. While no one-size-fits-all solution exists, companies can optimize their structures with proper guidance and planning to balance their compliance, flexibility, tax, and risk mitigation needs.